Welcome to our dedicated page for Rhythm Pharmaceu SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through a biotech filing that runs 300 pages of clinical data is hard enough; add rare-disease terminology and Rhythm Pharmaceuticals’ disclosures become downright daunting. Whether you need the latest Rhythm Pharmaceuticals quarterly earnings report 10-Q filing or want to track Rhythm Pharmaceuticals insider trading Form 4 transactions before the next data read-out, the challenge is finding what matters fast.
Stock Titan solves that problem. Our AI reads every 10-K, 10-Q, 8-K and proxy statement the moment it posts to EDGAR and delivers plain-language highlights—think cash runway trends, pivotal-trial costs, and patent-expiry clocks—so you can focus on decisions, not deciphering jargon. Looking for Rhythm Pharmaceuticals annual report 10-K simplified? It’s already condensed. Need Rhythm Pharmaceuticals Form 4 insider transactions real-time? Alerts arrive in seconds.
- AI-powered summaries that answer “understanding Rhythm Pharmaceuticals SEC documents with AI” in minutes
- Real-time feeds for Rhythm Pharmaceuticals executive stock transactions Form 4
- Side-by-side comparison of sequential trials inside every 10-Q earnings report filing analysis
- Key excerpts from Rhythm Pharmaceuticals proxy statement executive compensation—RSUs, milestone bonuses and all
- Rhythm Pharmaceuticals 8-K material events explained in plain English, from FDA label updates to financing rounds
Investors use these insights to monitor insider sentiment ahead of top-line data, gauge cash burn vs. runway, and benchmark executive incentives against regulatory goals. No more scrolling line-by-line; our platform surfaces what biopharma specialists actually need—from patient enrollment numbers to royalty obligations—so your biotech diligence stays sharp and timely.
Rhythm Pharmaceuticals (Nasdaq: RYTM) filed an 8-K disclosing the June 24 2025 Annual Meeting results and a governance change.
- Officer exculpation amendment: Stockholders approved a charter change (55.5 M FOR / 3.5 M AGAINST) extending Delaware-permitted liability protection to certain officers; became effective upon June 25 2025 filing.
- Director elections: Jennifer Good re-elected with 55.6 M votes; Edward T. Mathers retained his seat with 35.2 M votes.
- Auditor confirmation: Ernst & Young LLP ratified for FY-2025 with 60.6 M (99.7 %) FOR.
- Say-on-pay: Executive compensation passed (40.9 M FOR, 18.1 M AGAINST).
- Quorum: 60.7 M votes present, representing 92.7 % of eligible votes.
No operational or financial metrics were updated; the lone material item is the officer liability shield, which may dilute shareholder recourse.
FAQ
What is the current stock price of Rhythm Pharmaceu (RYTM)?
What is the market cap of Rhythm Pharmaceu (RYTM)?
